מונטלוקאסט - תרימה 4 מג Israele - ebraico - Ministry of Health

מונטלוקאסט - תרימה 4 מג

trima israel pharmaceutical products maabarot ltd - montelukast as sodium salt - טבליות לעיסות - montelukast as sodium salt 4 mg - montelukast - montelukast - montelukast - trima is indicated in adult and pediatric patients 2 years of age and older for the prophylaxis and chronic treatment of asthma, including prevention of daytime and nighttime symptoms, the treatment of aspirin-sensitive asthmatic patients, and the prevention of exercise-induced bronchoconstriction. montelukast - trima is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. montelukast - trima and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. montelukast - trima is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older.

מונטלוקאסט - תרימה 5 מג Israele - ebraico - Ministry of Health

מונטלוקאסט - תרימה 5 מג

trima israel pharmaceutical products maabarot ltd - montelukast as sodium salt - טבליות לעיסות - montelukast as sodium salt 5 mg - montelukast - montelukast - montelukast - trima is indicated in adult and pediatric patients 2 years of age and older for the prophylaxis and chronic treatment of asthma, including prevention of daytime and nighttime symptoms, the treatment of aspirin-sensitive asthmatic patients, and the prevention of exercise-induced bronchoconstriction. montelukast - trima is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. montelukast - trima and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. montelukast - trima is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older.

מונטלוקאסט - תרימה 10 מג Israele - ebraico - Ministry of Health

מונטלוקאסט - תרימה 10 מג

trima israel pharmaceutical products maabarot ltd - montelukast as sodium salt - טבליה - montelukast as sodium salt 10 mg - montelukast - montelukast - montelukast - trima is indicated in adult and pediatric patients 2 years of age and older for the prophylaxis and chronic treatment of asthma, including prevention of daytime and nighttime symptoms, the treatment of aspirin-sensitive asthmatic patients, and the prevention of exercise-induced bronchoconstriction. montelukast - trima is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. montelukast - trima and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. montelukast - trima is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older.

מונטהלוקאסט אינובמד 5 מ"ג Israele - ebraico - Ministry of Health

מונטהלוקאסט אינובמד 5 מ"ג

inovamed ltd - montelukast as sodium 5 mg - chewable tablets - montelukast - montelukast inovamed is indicated in pediatric patients 6 to 14 years of age for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction.montelukast inovamed is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. montelukast inovamed and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. montelukast inovamed is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 6 to 14 years of age.

מונטהלוקאסט אינובמד 4 מ"ג Israele - ebraico - Ministry of Health

מונטהלוקאסט אינובמד 4 מ"ג

inovamed ltd - montelukast as sodium 4 mg - chewable tablets - montelukast - montelukast inovamed is indicated in pediatric patients 2 to 5 years of age for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction. montelukast inovamed is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. montelukast inovamed and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. montelukast inovamed is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 2 to 5 years of age.

מונטהלוקאסט אינובמד 10 מ"ג Israele - ebraico - Ministry of Health

מונטהלוקאסט אינובמד 10 מ"ג

inovamed ltd - montelukast as sodium 10 mg - film coated tablets - montelukast - montelukast inovamed is indicated in adult and adolescents 15 years of age and older for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction.montelukast inovamed is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. montelukast inovamed and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. montelukast inovamed is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and adolescents 15 years of age and older.

טרקליר 62.5 מג Israele - ebraico - Ministry of Health

טרקליר 62.5 מג

j-c health care ltd - bosentan - טבליות מצופות פילם - bosentan 62.5 mg - bosentan - bosentan - treatment of pulmonary arterial hypertension (pah) in patients of who functional class ii-iv.reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease